Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.31 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4120937 | 1.00 | AKR1C4 (0.33) | AKR1C4AKR1C3KMT2ALMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL3696446 | 0.85 | HTR6 (0.39) | AKR1C4AKR1C3LMNASMN1; SMN2FFAR1 | |
| Fumaric Acid SCHEMBL3696438 | 0.85 | HTR6 (0.39) | AKR1C4AKR1C3LMNASMN1; SMN2FFAR1 | |
| Fumaric Acid SCHEMBL3693956 | 0.81 | AKR1C4 (0.33) | AKR1C4AKR1C3KMT2ALMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL3693954 | 0.81 | AKR1C4 (0.33) | AKR1C4AKR1C3KMT2ALMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL3703509 | 0.80 | RAB9A (0.36) | AKR1C4AKR1C3KMT2ALMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL3696949 | 0.80 | FFAR1 (0.35) | AKR1C4AKR1C3KMT2ALMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL3703504 | 0.80 | RAB9A (0.36) | AKR1C4AKR1C3KMT2ALMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL3696944 | 0.80 | FFAR1 (0.35) | AKR1C4AKR1C3KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4120943 | 0.80 | HCAR2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | KMT2A 4776/4885MEN1 1910/4885AKR1C4 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.